checkAd

     141  0 Kommentare Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta and Nucynta ER - Seite 2

    Investor Contact:
    Christopher James, M.D.                                                                                       
    Vice President, Investor Relations
    ir@collegiumpharma.com

    Lesen Sie auch

    Media Contact:
    Marissa Samuels
    Vice President, Corporate Communications
    communications@collegiumpharma.com


    Seite 2 von 2




    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta and Nucynta ER - Seite 2 STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) - Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today …